NanoZolid® - technology

Today's cancer treatments are given in the form of tablets, injections or infusion. It makes the whole body is exposed to the drugs and side effects, not just the tumor itself. Exposing even healthy tissue for potent drugs can lead to unnecessarily severe side effects. LIDDS has developed a technology that makes it possible to place the cancer drug where it does the most good. Slightly simplified, one can say that LIDDS with its proprietary technology, NanoZolid® formulate the active drug, which can then be injected into the tumor area. It can lead to faster output and less severe side effects. Additionally, LIDDS technology make it possible for the drug to exert its effect in the tumor area for up to six months, without the patient having to take their medicine every day.


A technology with many uses

LIDDS unique proprietary drug carriers can be used to develop new locally acting drugs for a wide range of cancers, such as tumors of the prostate, lung, ovarian, liver, brain, abdominal cavity, spine, head / neck, bone, uterus, kidney and bladder . Moreover, new treatments are developed to other intractable diseases that currently require systemic therapy to achieve high local drug concentrations. LIDDS has a unique and patented technology for local drug delivery that creates several advantages: • The formulation provides controlled release of drugs in the desired time up to six months. • Pharmaceutical preparation reabsorbed completely into the tissue due to its water solubility. • The drug is not adversely affected by the integration of LIDDS technology. • The formulation reduces the risk of accidental so-called dose-dumping, i.e. the drug is leaking uncontrollably.


Manufacturing Process and Technology

LIDDS NanoZolid® has developed a unique manufacturing process for its drug products which schematically can be described with three main steps, according to the figures below:


Agreements with Recipharm

LIDDS signed in 2015 an exclusive production agreement with Recipharm as in connection with the agreement invested 5 million in LIDDS. LIDDS and Recipharm has devoted significant time and resources to scale up production ahead of the next study and future commercial launches of its drug products.